SCHEMBL43978

SCHEMBL43978

CC(N1C(=O)C=CC1=O)N1C(=O)C=CC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 15/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GMNN O75496 1/20 0.39
THPO P40225 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
FAAH O00519 6/20 0.37
HSP90AA1 P07900 2/20 0.33
CCR6 P51684 1/20 0.33
TLR9 Q9NR96 2/20 0.32
TP53 P04637 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
XBP1 P17861 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13743120 0.85 MGLL (0.35) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL29017 0.81 MGLL (0.45) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL4841161 0.80 GSK3A (0.31) MGLLGSK3AGSK3B
SCHEMBL13968985 0.77 MGLL (0.41) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL331187 0.77 MGLL (0.41) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL969752 0.77 MGLL (0.41) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL13742892 0.77 MGLL (0.41) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL19546122 0.77 MGLL (0.41) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL22289873 0.77 MGLL (0.41) MGLLGSK3AGSK3BALDH1A1LMNA
SCHEMBL9634966 0.77 ALDH1A1 (0.37) MGLLGSK3AGSK3BALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260126453-A1 Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof THE BINDING SITE GROUP LTD (GB) 2026-05-07 US claimed
US-12560608-B2 Detection of molecular associations CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2026-02-24 US claimed
US-20260043066-A1 COMPOSITIONS AND METHODS RELATED TO KETHOXAL DERIVATIVES THE UNIVERSITY OF CHICAGO (US) 2026-02-12 US claimed
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2025-11-18 US claimed
WO-2025235971-A1 METHODS FOR DETECTING DNA SEQUENCE VARIATION IN THICK TISSUE SECTIONS THE JOHNS HOPKINS UNIVERSITY (US) 2025-11-13 WO claimed
US-12461108-B2 Mass spectrometry kit including a cross-linked antibody or fragment thereof THE BINDING SITE GROUP LIMITED (GB) 2025-11-04 US claimed
US-20250295745-A1 CROSS-LINKED TUMOR LYSATE SPHERICAL NUCLEIC ACIDS AS CANCER VACCINES NORTHWESTERN UNIVERSITY 2025-09-25 US claimed
EP-4615969-A1 METHODS FOR DETECTING RNA AND MOLECULAR ANALYSIS IN THICK TISSUE SECTIONS The Johns Hopkins University (US) 2025-09-17 EP claimed
US-20250179125-A1 Alpha-sheet Polypeptides and Their Use UNIVERSITY OF WASHINGTON 2025-06-05 US claimed
EP-4541374-A2 DEFINED MULTI-CONJUGATE OLIGONUCLEOTIDES Mpeg LA, L.l.c. (US) 2025-04-23 EP claimed
EP-1549350-B1 PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES FRESENIUS KABI DE GMBH (DE) 2008-09-24 EP claimed
US-20080181965-A1 Loaded latex optical molecular imaging probes QUANTUM MEDICAL HOLDINGS, LLC 2008-07-31 US claimed
US-20070254311-A1 Covalent modification and conjugation of luciferase CARDIOGENICS INC. (CA) 2007-11-01 US claimed
WO-2006094826-A2 METHOD FOR COUPLING ENZYMATICALLY ACTIVATED GLYCOCONJUGATES TO A HYDROXYALKYL STARCH FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2006-09-14 WO claimed
US-20060165677-A1 DELETION FORMS OF IgE-DEPENDENT HISTAMINE RELEASING FACTOR HAVING HISTAMINE RELEASING ACTIVITY, HRF-BINDING PEPTIDES AND THE USES THEREOF EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2006-07-27 US claimed
EP-1683866-A2 Deletion forms of IgE-dependent histamine releasing factor having histamine-releasing activity, HRF-binding peptides and the uses thereof Ewha University-Industry Collaboration Foundation (KR) 2006-07-26 EP claimed
US-20060100163-A1 Pharmaceutically active oligosaccharide conjugates FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2006-05-11 US claimed
US-20050176642-A1 Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric GP120 UNIVERSITY OF MARYLAND, BALTIMORE 2005-08-11 US claimed
EP-1549350-A1 PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES Fresenius Kabi Deutschland GmbH (DE) 2005-07-06 EP claimed
WO-2004032971-A1 PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2004-04-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080181965-A1 Loaded latex optical molecular imaging probes MLX, LOXL1, EPX MGLL 38/4885GSK3A 4395/4885GSK3B 4307/4885
US-20260126453-A1 Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof IGLV6-57, IGSF11, FCGR3B MGLL 3531/4885GSK3A 4449/4885GSK3B 4491/4885
US-20260043066-A1 COMPOSITIONS AND METHODS RELATED TO KETHOXAL DERIVATIVES RNMT, SMCHD1, PKLR MGLL 1183/4885GSK3A 2413/4885GSK3B 2327/4885
US-20050176642-A1 Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric GP120 CD4, CD40LG, NECTIN4 MGLL 2728/4885GSK3A 1869/4885GSK3B 1730/4885
US-12560608-B2 Detection of molecular associations APP, SPPL2A, SPPL2B MGLL 4623/4885GSK3A 4332/4885GSK3B 4338/4885
US-20250179125-A1 Alpha-sheet Polypeptides and Their Use IAPP, APP, PRNP MGLL 2722/4885GSK3A 1231/4885GSK3B 1476/4885
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality NCL, NSUN3, POLN MGLL 4186/4885GSK3A 4392/4885GSK3B 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.